由于证据不利于普��PSA测试，因此急需新的筛查测试和生物标记。 它们应能有效区别具有潜在生命危险的前列腺癌和危险性较小的前列腺癌。
As evidence tilts the balance away from widespread PSA testing, a new screening test or biomarker is urgently needed that can distinguish effectively between potentially life-threatening prostate cancers and less dangerous forms.